Trellis Bioscience LLC (Trellis) and Open Monoclonal Technology, Inc. (OMT) today announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMT's OmniRat™ platform. Trellis will apply its CellSpot™ antibody screening technology to libraries of OmniRat-generated B cells to discover high affinity, ultra rare antibodies with precisely defined specificity. Trellis will advance and partner each program and share the deal economics with OMT depending on the stage of development.
“We are pleased to collaborate with Trellis to capture the synergies of our complementary antibody discovery technologies. This collaboration further illustrates OMT's ability to partner with a range of companies to produce human therapeutic antibodies.”
Stote Ellsworth, Trellis CEO and President, said: "Trellis' CellSpot platform has shown in four consecutive programs the unique ability to mine rare, best-in-class therapeutic antibodies directly from human blood. In addition to our native human approach, the collaboration with OMT will leverage Trellis' powerful multiplexed screening in the context of antibody libraries generated with the OmniRat platform. This will allow Trellis to expand into new therapeutic areas and expand its commercial opportunities, particularly in the field of cancer."
Dr. Roland Buelow, OMT CEO and Founder, continued: "We are pleased to collaborate with Trellis to capture the synergies of our complementary antibody discovery technologies. This collaboration further illustrates OMT's ability to partner with a range of companies to produce human therapeutic antibodies."
COVID-19 booster enhances virus neutralizing antibodies in breast milk, new study reveals